CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas

被引:35
作者
Venkataramani, Vivek [1 ,2 ]
Kueffer, Stefan [3 ]
Cheung, Kenneth C. P. [4 ]
Jiang, Xuejun [2 ]
Truemper, Lorenz [1 ]
Wulf, Gerald G. [1 ]
Stroebel, Philipp [3 ]
机构
[1] Univ Med Ctr Gottingen UMG, Dept Hematol & Med Oncol, Gottingen, Germany
[2] Mem Sloan Kettering Canc Ctr, Cell Biol Program, Gottingen, Germany
[3] Univ Med Ctr Gottingen UMG, Inst Pathol, Gottingen, Germany
[4] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London, England
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; CELL-PROLIFERATION; METASTATIC ANGIOSARCOMA; PROTEIN; HEMANGIOENDOTHELIOMA; LYMPHANGIOSARCOMA; MECHANISM; APOPTOSIS; OUTCOMES; FUSION;
D O I
10.1158/1078-0432.CCR-17-1778
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Angiosarcomas are soft tissue sarcomas with endothelial differentiation and vasoformative capacity. Most angiosarcomas show strong constitutive expression of the endothelial adhesion receptor CD31/PECAM-1 pointing to an important role of this molecule. However, the biological function of CD31 in angiosarcomas is unknown. Experimental Design: The expression levels of CD31 in angiosarcoma cells and its effects on cell viability, colony formation, and chemoresistance were evaluated in human angiosarcoma clinical samples and in cell lines through isolation of CD31(high) and CD31(low) cell subsets. The redox-regulatory CD31 function linked to YAP signaling was determined using a CD31-blocking antibody and siRNA approach and was further validated in CD31-knockout endothelial cells. Results: We found that most angiosarcomas contain a small CD31(low) cell population. CD31(low) cells had lost part of their endothelial properties and were more tumorigenic and chemoresistant than CD31(high) cells due to more efficient reactive oxygen species (ROS) detoxification. Active downregulation of CD31 resulted in loss of endothelial tube formation, nuclear accumulation of YAP, and YAP-dependent induction of antioxidative enzymes. Addition of pazopanib, a known enhancer of proteasomal YAP degradation resensitized CD31(low) cells for doxorubicin resulting in growth suppression and induction of apoptosis. Conclusions: Human angiosarcomas contain a small aggressive CD31low population that have lost part of their endothelial differentiation programs and are more resistant against oxidative stress and DNA damage due to intensified YAP signaling. Our finding that the addition of YAP inhibitors can resensitize CD31(low) cells toward doxorubicin may aid in the rational development of novel combination therapies to treat angiosarcomas. (C) 2017 AACR.
引用
收藏
页码:460 / 473
页数:14
相关论文
共 48 条
  • [1] A PERMANENT HUMAN CELL-LINE (EA.HY926) PRESERVES THE CHARACTERISTICS OF ENDOTHELIN-CONVERTING ENZYME FROM PRIMARY HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS
    AHN, K
    PAN, S
    BENINGO, K
    HUPE, D
    [J]. LIFE SCIENCES, 1995, 56 (26) : 2331 - 2341
  • [2] Anderson T, 2015, AM J SURG PATHOL, V39, P132, DOI 10.1097/PAS.0000000000000346
  • [3] Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma
    Antonescu, Cristina R.
    Le Loarer, Francois
    Mosquera, Juan-Miguel
    Sboner, Andrea
    Zhang, Lei
    Chen, Chun-Liang
    Chen, Hsiao-Wei
    Pathan, Nursat
    Krausz, Thomas
    Dickson, Brendan C.
    Weinreb, Ilan
    Rubin, Mark A.
    Hameed, Meera
    Fletcher, Christopher D. M.
    [J]. GENES CHROMOSOMES & CANCER, 2013, 52 (08) : 775 - 784
  • [4] Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis
    Basu, S
    Totty, NF
    Irwin, MS
    Sudol, M
    Downward, J
    [J]. MOLECULAR CELL, 2003, 11 (01) : 11 - 23
  • [5] Management of angiosarcoma.
    Budd G.T.
    [J]. Current Oncology Reports, 2002, 4 (6) : 515 - 519
  • [6] CD31 signals confer immune privilege to the vascular endothelium
    Cheung, Kenneth
    Ma, Liang
    Wang, Guosu
    Coe, David
    Ferro, Riccardo
    Falasca, Marco
    Buckley, Christopher D.
    Mauro, Claudio
    Marelli-Berg, Federica M.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (43) : E5815 - E5824
  • [7] Choudhury Y, 2017, SCI REP-UK, V7, DOI [10.1038/srep41238, 10.1038/srep46391]
  • [8] INHIBITION OF GLYCOGEN-SYNTHASE KINASE-3 BY INSULIN-MEDIATED BY PROTEIN-KINASE-B
    CROSS, DAE
    ALESSI, DR
    COHEN, P
    ANDJELKOVICH, M
    HEMMINGS, BA
    [J]. NATURE, 1995, 378 (6559) : 785 - 789
  • [9] Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma
    D'Angelo, Sandra P.
    Munhoz, Rodrigo R.
    Kuk, Deborah
    Landa, Johnathan
    Hartley, Eliza W.
    Bonafede, Michael
    Dickson, Mark A.
    Gounder, Mrinal
    Keohan, Mary L.
    Crago, Aimee M.
    Antonescu, Cristina R.
    Tap, William D.
    [J]. ONCOLOGY, 2015, 89 (04) : 205 - 214
  • [10] Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
    D'Angelo, Sandra P.
    Mahoney, Michelle R.
    Van Tine, Brian A.
    Adkins, Douglas R.
    Perdekamp, Maria T. Grosse
    Condy, Mercedes M.
    Luke, Jason J.
    Hartley, Eliza Woodward
    Antonescu, Cristina R.
    Tap, William D.
    Schwartz, Gary K.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 629 - 638